Abstract:3549 Background: Patients with metastatic colorectal cancer (mCRC) can achieve no evidence of disease (NED) after curative treatment. However, how to precisely guide the treatment after NED remained to be explored. Minimal residual disease (MRD) detection using circulating tumor DNA (ctDNA) analysis has shown to help identify patients’ risk of relapse in early-stage CRC. Thus we aimed to explore the feasibility of ctDNA by a tumor-informed personalized approach to predict recurrence and guide chemotherapy in mCRC with NED. Methods: We enrolled mCRC patients who achieved NED after local curative treatment from June 2022 to December 2023. Surgical or puncture tissues were collected. Blood samples were collected prior to curative treatment, at 1 month after curative treatment, and subsequently every 2–3 months until disease progression or completion of a 2-year follow-up period. Tumor-derived variants were identified by whole-exon sequencing of the tissue samples. Up to 50 highly ranked variants were selected for the personalized panel design, which was used to assess the MRD status of blood samples. Patients with negative MRD post curative treatment were followed, while those with positive MRD were subjected to investigator-determined adjuvant chemotherapy (ACT). Results: A total of 106 mCRC patients with NED after curative treatment were enrolled. The ctDNA was detected in 62 patients (92.5%, 62/67) pre curative treatment and in 55 patients (51.9%, 55/106) post curative treatment. At a median follow-up period of 252 days, 42 patients experienced recurrence and 33 patients (78.6%) had positive ctDNA post curative treatment. Patients with positive ctDNA post curative treatment demonstrated an inferior recurrence-free survival (RFS) than those with negative ctDNA (HR: 4.58, 95% CI: 2.18–9.64; P<0.001), which was not observed by CEA (HR: 1.87, 95% CI: 0.84–4.15; P=0.12). In patients with negative ctDNA after curative treatment, there was no difference in RFS between those treated with ACT or not (HR: 2.51, 95% CI: 0.48–13.04; P=0.25). During the dynamic longitudinal monitoring of ctDNA, the median RFS was 5.6 months, 15.5 months, 10.2 months and unreached in patients with persistently positive ctDNA, converted negative ctDNA, converted positive ctDNA, and persistently negative ctDNA, respectively (log-rank P for trend <0.001). All recurrent patients had at least one positive ctDNA detection before imaging confirmed recurrence, and the median lead time interval of ctDNA positivity to radiographic recurrence was 112 days (range, 3–441 days). Conclusions: Our results demonstrated that patients with ctDNA negative post curative treatment had superior RFS compared with those with positive ctDNA. Post curative treatment and dynamic ctDNA had the potential to guide ACT in mCRC patients with NED. The follow-up is still on-going. Clinical trial information: NCT05635630 .

Preoperative liquid biopsy for optimal patient selection in metastatic colorectal cancer

Circulating Tumor DNA As a Promising Biomarker of Relapse Risk for Stage II-III Colorectal Cancer.

Perioperative Circulating Tumor DNA in Colorectal Liver Metastases: Concordance with Metastatic Tissue and Predictive Value for Tumor Burden and Prognosis

Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases

Pre-hepatectomy Dynamic Circulating Tumor DNA to Predict Pathologic Response to Preoperative Chemotherapy and Post-Hepatectomy Recurrence in Patients with Colorectal Liver Metastases.

Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment

Postoperative circulating tumor DNA testing based on tumor naïve strategy after liver metastasis surgery in colorectal cancer patients

Prognostic value of circulating tumor DNA following local therapy in colorectal cancer with liver metastases.

Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer

Kinetics of postoperative circulating cell-free DNA and impact on minimal residual disease detection rates in patients with resected stage I-III colorectal cancer.

Effect of dynamic circulating tumor DNA minimal residual disease detection on recurrence surveillance and second resection rate after curative intent resection of colorectal liver metastasis: A prospective cohort study.

Feasibility of ctDNA in detecting minimal residual disease and predicting recurrence for colorectal cancer liver metastases

Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial

Use of circulating tumor DNA analysis to predict recurrence and need for adjuvant chemotherapy in stage I-IV colorectal cancer.

Surveillance of resected metastatic colorectal cancer utilizing circulating DNA.

Utility of Circulating Tumor DNA Assessment in Characterizing Recurrence Sites after Optimal Resection for Metastatic Colorectal Cancer

Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA

Personalized circulating tumor DNA monitoring improves recurrence surveillance and management after curative resection of colorectal liver metastases: A prospective cohort study

Circulating tumor DNA analysis predicts recurrence and avoids unnecessary adjuvant chemotherapy in I–IV colorectal cancer

Correlation of Circulating Tumor DNA and Recurrence in Patients with Metastatic Colorectal Cancer with No Evidence of Disease: an Open-Label, Prospective, Phase II Study.

Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies